Moving Beyond Limitations in ADHD Management: Best Practices for Personalized Therapy for Children and AdultsPremiere Date: Monday, January 31, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, January 31, 2023
|Ann Childress, MD (Moderator)
President, Center for Psychiatry and Behavioral Medicine, Inc.
Associate Professor Child/Adolescent Psychiatry
Touro University Nevada College of Osteopathic Medicine
Clinical Associate Professor
University of Nevada, Las Vegas School of Medicine
Las Vegas, NV
|Timothy E. Wilens, MD
Chief, Division of Child & Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School
Attention-deficit/hyperactivity disorder (ADHD) is a common, persistent, and impairing disorder that can occur throughout the lifespan and persist into adulthood. Several therapies, including stimulants and non-stimulants, are available for the management of ADHD; however, determining which therapy is best suited for the individual can be challenging. It is therefore imperative to differentiate the available therapies for ADHD based on their safety, efficacy, tolerability, formulations, and duration of effect to personalize treatment selection. As ADHD is a lifelong disorder, optimal outcomes are best achieved through a team-based management approach.
For clinical pearls on optimal strategies to personalize care for children and adults with ADHD, join our faculty experts for this third installment in theCME Outfitters series “ADHD Can Be a Moving Target: Equip Yourself with the Tools to Detect and Manage ADHD to Reduce Its Burden.”
At the end of this CE activity, participants should be able to:
- Develop personalized treatment strategies for children and adults with ADHD that consider safety, efficacy, and formulation as well as individual preferences and personal goals for therapy.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry and/or pediatrics
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Childress reports the following financial relationships:
Consultant: : Aardvark Therapeutics, Inc.; Corium Inc.; Jazz Pharmaceuticals, Inc.; KemPharm, Inc.; Lumos Pharma; Neos Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Tulex Pharmaceuticals
Research Support: : Adlon Therapeutics L.P.; Akili Interactive Labs, Inc.; Allergan; Arbor Pharmaceuticals; KemPharm, Inc.; Neos Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Speakers Bureau: Corium Inc.; Ironshore Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.
Other Financial or Material Support: Writing support for Purdue Pharma L.P.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Wilens reports the following financial relationships:
Consultant: Arbor Pharmaceuticals; Bay Cove Human Services, Inc.; Ironshore Pharmaceuticals Inc; Gavin Foundation; KemPharm, Inc.; Otsuka America Pharmaceutical, Inc; Vallon Pharmaceuticals; US Minor/Major League Baseball;US National Football League (ERM Associates); and White Rhino/3D
Grants and Research Support: NIH National Institute on Drug Abuse (NIDA)
Royalties: Cambridge University Press; Guildford Press; Ironshore Pharmaceuticals Inc.
Other Financial or Material Support: Massachusetts General Hospital (Employee)
The following Peer Reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).